IFNG and adult-onset Still disease: Luckily, new therapies to target central pathophysiological components of AOSD are already on the way: Emapalumab (64), an anti-IFNγ antibody, janus kinase (JAK) inhibitors (65–67), and tadekinig alfa (68), a recombinant IL-18 binding protein, are being evaluated for the treatment of AOSD.